Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Atrasentan | 173937-91-2 | C29H38N2O6 | 5 MG
Supplier: Medchemexpress LLC HY154035MG
Atrasentan (ABT-627) is an endothelin receptor antagonist that targets ETA with an IC50 of 0.055 nM. It significantly inhibits LNCaP and C4-2b prostate cancer cell growth and also induces several CYPs and drug transporters. It is intended for research use only.
- Endothelin receptor antagonist
- Targets ETA receptor
- Inhibits LNCaP and C4-2b prostate cancer cell growth
- Down-regulates NF-κB DNA binding activity
- Induces CYPs and drug transporters
- Moderate P-gp inhibitor
- Weak BCRP inhibitor
- Inhibits pressor response induced by big endothelin-1 in pithed rats
- Inhibits C4-2b tumor growth within the bone environment
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?